Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. by Jubb, A, Miller, K, Rugo, H, Harris, A, Chen, D, Reimann, J, Cobleigh, M, Schmidt, M, Langmuir, V, Hillan, K, Chen, D, Koeppen, H

Bridging the “Know-Do” Gaps in Five Non-Communicable Diseases Using a Common Framework Driven by Implementation Science by Donohue JF, Elborn JS, Lansberg P, Javed A, Tesfaye S, Rugo H, Duddi SRD, Jithoo N, Huang PH, Subramaniam K, Ramanjinappa N, Koltun A, Melamed S, Chan JCN

Get full text

Alpelisib plus fulvestrant in PIK3CA-Altered and PIK3CA-wild-type estrogen receptor–positive advanced breast cancer: A phase 1b clinical trial by Juric, D, Janku, F, Rodón, J, Burris, H, Mayer, I, Schuler, M, Seggewiss-Bernhardt, R, Gil-Martin, M, Middleton, M, Baselga, J, Bootle, D, Demanse, D, Blumenstein, L, Schumacher, K, Huang, A, Quadt, C, Rugo, H